COMMENTS ON PUBLISHED PAPERS

Serum levels of soluble ICAM-1 in acute leukemia patients with chemotherapyinduced neutropenia
In a recent article in Leukemia, Südhoff et al 1 described was pneumonia as defined by Sü dhoff et al. The majority of increased serum levels of soluble ICAM-1 (sICAM-1) during our patients had septicemia/bacteremia (11/16), and a mincomplicating infections in acute leukemia patients with ority (4/16) had clinical signs of local infections other than chemotherapy-induced neutropenia. The majority of their pneumonia. The increase in serum sICAM-1 concentrations patients had either fever of unknown origin or documented during infection was generally lower for our patients than for pneumonia, and only a small group had other documented the pneumonia patients described in Sü dhoff's study, and an infections. Serum concentrations of sICAM-1 increased during increase exceeding 300 ng/ml was detected only for three of infections, particularly in patients with pneumonia. An our patients. These three patients had the following infections: increase in serum levels exceeding 300 ng/ml was especially (1) one patient had a perianal abscess which later developed detected in patients with pneumonia and seemed to disinto a chronic perianal fistula; (2) one patient had a severe tinguish these patients from those with fever not related to perianal infection without development of abscess; (3) the last pneumonia. 1 patient had a urinary tract infection without evidence of sepIn a previous article, we described that serum levels of ticemia. sICAM-1 increased during complicating bacterial infections in When taking into account this additional clinical information, acute leukemia patients with chemotherapy-induced leukoour results seem to support the conclusion reached by Südhoff penia. 2 Our investigations have later been extended, and we et al that the increase in serum sICAM-1 levels is particularly high presented our overall results in a recent review. 3 As pointed in patients with pneumonia. In contrast to Südhoff's patients with out by Sü dhoff et al 1 , our previous reports did not include pneumonia, our patients with bacteremia/septicemia usually had detailed information about physical examination and chest an increase in serum sICAM-1 levels less than 300 ng/ml. One radiographs for our patients, and it was therefore difficult for possible explanation for the difference between pneumonia and Sü dhoff et al to compare their results with the results from bacteremia patients could be that there are differences in the our investigations.
pathogenesis of inflammatory responses between the lungs and Several patients with pneumonia were included in Sü dhoff's other organs. 1 However, patients with chemotherapy-induced study, whereas only one out of 16 infections in our patients neutropenia are severely immunocompromised, and due to their inadequate inflammatory responses local signs of infection will often be absent. An alternative explanation for the differences in patients may therefore be differences in the inflammatory 
Reply to O / Bruserud: Increases of sICAM-1 in neutropenic fever
We appreciate the more detailed description of infectious The question whether levels of sICAM-1 in neutropenic patients with pneumonia are generally higher than in patients with complications in chemotherapy-induced neutropenia by Dr Bruserud. 1 In their study, sICAM-1 levels in a small group of localized infections at other sites cannot be answered by these two studies. Nevertheless, it is tempting to conclude from data patients (three out of 16) exceeded the threshold of Ͼ300 g/l which was highly diagnostic for pneumonia in our study.
presented by Bruserud et al and our group that strong increases of sICAM-1 in neutropenic fever are associated with severe localized Interestingly, these three patients had clinically relevant localized inflammation different from pneumonia such as infections rather than with systemic bacteremia or septicemia. perianal abscess and urinary tract infection.
When comparing the absolute levels of sICAM-1 in the two T Sü dhoff Department of Hematology and Oncology, A Wehmeier Heinrich-Heine-University Dü sseldorf, studies it has to be considered that sICAM-1 measurements were performed with different immunoassays and in different Dü sseldorf, Germany media (EDTA plasma vs serum).
Besides such technical aspects, the liberation of sICAM-1 from inflamed tissue may depend on the duration and severity of infection and, as stated by Dr Bruserud, on the organ-specific immune References response. In animal models, considerable variability in ICAM-1 expression on endothelial cells in different tissues has been high levels of circulating ICAM-1 during neutropenic pneumonia.
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